Kynan Feeney

7.2k total citations
28 papers, 308 citations indexed

About

Kynan Feeney is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Kynan Feeney has authored 28 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Kynan Feeney's work include Cancer Immunotherapy and Biomarkers (13 papers), Gastric Cancer Management and Outcomes (6 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Kynan Feeney is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Gastric Cancer Management and Outcomes (6 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Kynan Feeney collaborates with scholars based in Australia, United States and Germany. Kynan Feeney's co-authors include Aisling Barry, David Speers, Ian Arthur, Niall C. Tebbutt, Anthony D. Keil, Gary K. Dowse, Yelena Y. Janjigian, Joseph Chao, James M. Cleary and Ming Lei and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and European Heart Journal.

In The Last Decade

Kynan Feeney

25 papers receiving 299 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kynan Feeney Australia	12	179	94	77	49	40	28	308
Eric Ballon‐Landa United States	9	78 0.4×	78 0.8×	58 0.8×	53 1.1×	41 1.0×	20	348
Victoria Rodríguez United States	6	163 0.9×	42 0.4×	116 1.5×	73 1.5×	15 0.4×	9	439
Benquan Wu China	9	109 0.6×	58 0.6×	30 0.4×	145 3.0×	123 3.1×	16	330
Shinichi Morinaga Japan	10	155 0.9×	28 0.3×	70 0.9×	95 1.9×	44 1.1×	23	436
Tara M. Allos United States	10	78 0.4×	103 1.1×	153 2.0×	84 1.7×	52 1.3×	12	434
Sílvia Silva Portugal	12	60 0.3×	90 1.0×	119 1.5×	80 1.6×	25 0.6×	26	347
Michael Castro United States	9	114 0.6×	89 0.9×	51 0.7×	44 0.9×	29 0.7×	28	277
Yizhen Chen China	9	67 0.4×	47 0.5×	38 0.5×	25 0.5×	41 1.0×	20	277
Marzia Franceschilli Italy	8	75 0.4×	44 0.5×	109 1.4×	60 1.2×	18 0.5×	21	296
Michael Bint Australia	7	68 0.4×	134 1.4×	43 0.6×	19 0.4×	18 0.5×	10	242

Countries citing papers authored by Kynan Feeney

Since Specialization

Citations

This map shows the geographic impact of Kynan Feeney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kynan Feeney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kynan Feeney more than expected).

Fields of papers citing papers by Kynan Feeney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kynan Feeney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kynan Feeney. The network helps show where Kynan Feeney may publish in the future.

Co-authorship network of co-authors of Kynan Feeney

This figure shows the co-authorship network connecting the top 25 collaborators of Kynan Feeney. A scholar is included among the top collaborators of Kynan Feeney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kynan Feeney. Kynan Feeney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Feeney, Kynan, L. van Leeuwen, Matthew L. Holzner, et al.. (2025). Secondary Perfusion: Modeling Viability of Organs Declined for Transplant. American Journal of Transplantation. 25(8). S94–S94.

Mercadé, T. Macarulla, Tanios Bekaii‐Saab, Kynan Feeney, et al.. (2025). 384TiP Quemliclustat and chemotherapy in previously untreated patients with metastatic pancreatic ductal adenocarcinoma: PRISM-1, a randomized, placebo-controlled, phase III trial. Annals of Oncology. 36. S147–S148.

Shitara, Kohei, Markus Moehler, Jaffer A. Ajani, et al.. (2024). Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.. Journal of Clinical Oncology. 42(16_suppl). 4040–4040. 3 indexed citations

Méndez, Guillermo, Joseph Chao, Radim Němeček, et al.. (2024). First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study. Journal of Clinical Oncology. 42(17). 2080–2093. 27 indexed citations

Paz‐Ares, Luis, Tudor–Eliade Ciuleanu, Manuel Cobo, et al.. (2022). First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.. Journal of Clinical Oncology. 40(17_suppl). LBA9026–LBA9026. 19 indexed citations

Brahmer, Julie R., T-E. Ciuleanu, Michael Schenker, et al.. (2020). 67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1. Annals of Oncology. 31. S1444–S1445. 3 indexed citations

Clarke, Stephen, Matthew Burge, Kynan Feeney, et al.. (2020). The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. PLoS ONE. 15(3). e0229900–e0229900. 13 indexed citations

Wainberg, Zev A., Kynan Feeney, Myung Ah Lee, et al.. (2020). Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. BMC Cancer. 20(1). 633–633. 21 indexed citations

Wainberg, Zev A., Kynan Feeney, Myung Ah Lee, et al.. (2019). Meta-analysis of OS for pancreatic cancer patients receiving 5FU and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy.. Journal of Clinical Oncology. 37(4_suppl). 202–202. 2 indexed citations

10.

Moehler, Markus, Yelena Y. Janjigian, Antoine Adenis, et al.. (2018). CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology. 36(4_suppl). TPS192–TPS192. 25 indexed citations

11.

Clarke, Stephen, Matthew Burge, Kynan Feeney, et al.. (2018). The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab.. Journal of Clinical Oncology. 36(4_suppl). 719–719. 3 indexed citations

12.

Hart, Nicolas H., Daniel A. Galvão, Christobel Saunders, et al.. (2018). Mechanical suppression of osteolytic bone metastases in advanced breast cancer patients: a randomised controlled study protocol evaluating safety, feasibility and preliminary efficacy of exercise as a targeted medicine. Trials. 19(1). 695–695. 11 indexed citations

13.

Hart, Nicolas H., Robert U. Newton, Nigel Spry, et al.. (2017). Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy. BMJ Open. 7(5). e014458–e014458. 18 indexed citations

14.

Feeney, Kynan, et al.. (2016). Safety of immune check-point inhibitors in patients with autoimmune conditions and advanced cancer. Annals of Oncology. 27. vi371–vi371. 1 indexed citations

15.

Feeney, Kynan, et al.. (2013). Mycobacterium mimicking metastatic melanoma. Internal Medicine Journal. 43(12). 1342–1346. 4 indexed citations

16.

Gibson, C. Michael, Pierluigi Tricoci, Kynan Feeney, et al.. (2013). Lack of concordance between angiographic core laboratory and CEC in the assessment of stent thrombosis: results from the TRACER angiographic substudy. European Heart Journal. 34(suppl 1). P240–P240. 2 indexed citations

17.

Hasani, Arman, Kynan Feeney, Anna K. Nowak, & Michael Millward. (2010). Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia. Asia-Pacific Journal of Clinical Oncology. 6(4). 350–356.

18.

Piccolo, Francesco Lo, et al.. (2008). Oxaliplatin‐induced interstitial lung disease. Asia-Pacific Journal of Clinical Oncology. 4(3). 175–180. 4 indexed citations

19.

Feeney, Kynan, et al.. (2007). Chemotherapy induced nausea and vomiting--prevention and treatment.. PubMed. 36(9). 702–6. 9 indexed citations

20.

Feeney, Kynan, et al.. (2005). Epidemiological features and control of an outbreak of scarlet fever in a Perth primary school. Communicable Diseases Intelligence. 29(4). 386–390. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact